---
title: Detect Parkinson protein changes early
nct_id: NCT04724941
status: RECRUITING
sponsor: University Hospital Schleswig-Holstein
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04724941"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04724941"
last_fetched: "2026-05-10T14:01:34.816Z"
source: "Parkinson's Pathways (curated)"
---
# Detect Parkinson protein changes early

**Goal (in five words):** Detect Parkinson protein changes early

**Official Title:** Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

**Trial ID:** [NCT04724941](https://clinicaltrials.gov/study/NCT04724941)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** University Hospital Schleswig-Holstein
- **Target Enrollment:** 2000 participants
- **Start Date:** 2021-06-01
- **Completion Date:** 2027-12
- **Conditions:** Parkinson Disease
- **Interventions:** No intervention
- **Intervention Types:** OTHER

## Summary For Families

The goal is to detect abnormal alpha-synuclein in people before they have clear Parkinson's symptoms, so researchers can identify biological signs of prodromal disease earlier. The approach is observational screening, collecting clinical measures and biological samples to look for alpha-synuclein biomarkers, with a lumbar puncture substudy that analyzes cerebrospinal fluid for misfolded alpha-synuclein, and no experimental treatments are given. The study plans to enroll up to 2000 adults aged 50 to 99 who do not have clinical Parkinson's. People with other significant neurologic or orthopedic conditions that affect motor assessment are excluded, and anyone with contraindications to lumbar puncture or on anticoagulants cannot participate in that substudy.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 99 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age between 50 and 99

Exclusion Criteria:

* Presence of clinical PD at the time of study inclusion
* Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
* other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
* in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
```

## Locations (1)

- Department for Neurology, University of Kiel, Kiel, Germany _(54.3213, 10.1349)_
  - Eva Schäffer, Dr. — (CONTACT) — 004943150023983 — eva.schaeffer@uksh.de

## Central Contacts

- Eva Schaeffer, Dr. — (CONTACT) — 004943150023983 — eva.schaeffer@uksh.de

---

*Canonical: https://parkinsonspathways.com/trial/NCT04724941*  
*HTML version: https://parkinsonspathways.com/trial/NCT04724941*  
*Source data: https://clinicaltrials.gov/study/NCT04724941*